Value and usability of unpublished data sources for systematic reviews and network meta-analyses

Evidence-Based Medicine

Volumn 21, Issue 6, 2016, Pages 208-213

  Halfpenny, Nicholas James Anthony ^a   Quigley, Joan Mary ^a   Thompson, Juliette Catherine ^a   Scott, David Alexander ^a  

^a ICON PLC   (United Kingdom)

Author keywords

HEALTH ECONOMICS; STATISTICS RESEARCH METHODS

Indexed keywords

PLACEBO; TOCILIZUMAB; TRAMETINIB;

ARTICLE; CANCER CHEMOTHERAPY; CLINICAL STUDY; DATA PROCESSING; EUROPEAN MEDICINES AGENCY; EVIDENCE BASED MEDICINE; FOOD AND DRUG ADMINISTRATION; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; META ANALYSIS (TOPIC); METASTATIC MELANOMA; MORTALITY; PEER REVIEW; PHASE 3 CLINICAL TRIAL (TOPIC); PUBLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGISTER; SCIENTIFIC LITERATURE; SYSTEMATIC REVIEW (TOPIC); CLINICAL TRIAL (TOPIC); INFORMATION RETRIEVAL; LITERATURE; NETWORK META-ANALYSIS; REPRODUCIBILITY; UNITED STATES;

CLINICAL TRIALS AS TOPIC; HUMANS; INFORMATION STORAGE AND RETRIEVAL; META-ANALYSIS AS TOPIC; NETWORK META-ANALYSIS; PUBLICATIONS; REGISTRIES; REPRODUCIBILITY OF RESULTS; REVIEW LITERATURE AS TOPIC; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84990173527     PISSN: 13565524     EISSN: 14736810     Source Type: Journal    
DOI: 10.1136/ebmed-2016-110494     Document Type: Article

References (40)

1. Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. 3/2011 2011. http://www. cochrane-handbook.org
2. Centre for Reviews and Dissemination. Systematic Reviews: CRD's guidance for undertaking reviews in health care. Centre for Reviews and Dissemination, 2009.
3. Manchikanti L. Evidence-based medicine, systematic reviews, and guidelines in interventional pain management, part I: introduction and general considerations. Pain Physician 2008;11:161-86.
4. Schlosser R. The role of systematic reviews in evidence-based practice, research, and development. National Centre for the Dissemination of Disability Research (NCDDR), 2008.
5. Laws A, Kendall R, Hawkins N. A comparison of national guidelines for network meta-analysis. Value Health 2014;17:642-54.
6. Quigley JM, Woods B, Thompson J, et al. Confronting heterogeneity: using systematic review effectively for meta-analysis. Value Health 2013;16:A612.
7. Hasselblad V. Meta-analysis of multitreatment studies. Med Decis Making 1998;18:37-43.
8. Caldwell DM, Ades AE, Higgins JP. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 2005;331:897-900.
9. Mahood Q, Van Eerd D, Irvin E. Searching for grey literature for systematic reviews: challenges and benefits. Res Synth Methods 2014;5:221-34.
10. Hopewell S, McDonald S, Clarke M, et al. Grey literature in meta-analyses of randomized trials of health care interventions. Cochrane Database Syst Rev 2007;(2):MR000010.
11. EMA. Posting of clinical trial summary results in European Clinical Trials Database (EudraCT) to become mandatory for sponsors as of 21 July 2014.
12. 2014. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news-and-events/news/2014/06/news-detail-002127.jsp&mid=WC0b01ac058004d5c1
13. EMA Committee for medicinal products for human use (CHMP). Time allowed for applicants to respond to questions and issues raised during the assessment of new marketing authorisation applications in the centralised procedure. 2009 (EMEA/75401/2006 Rev. 2). http://www.ema. europa.eu/docs/en-GB/document-library/Regulatory-and-procedural-guideline/2009/10/WC500005056.pdf (accessed 16 Sept 2016).
14. FDA. Suggested format for developing and responding to deficiencies in accordance with the least burdensome provisions of FDAMA; final guidance for industry and FDA staff. 2000. http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm073680.pdf (accessed 16 Sept 2016).
15. Bryden P, Quigley J, Padhiar A, et al. The relative efficacy and safety of simeprevir-based triple therapy compared to boceprevir and telaprevir in treatment-naïve patients chronically infected with hepatitis C virus genotype 1: Bayesian network meta-analyses. Liver Meeting; 2013.
16. Dong YH, Lin HH, Shau WY, et al. Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomised controlled trials. Thorax 2013;68:48-56.
17. Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012;367:107-14.
18. Schadendorf D, Amonkar MM, Milhem M, et al. Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study. Ann Oncol 2014;25:700-6.
19. GlaxoSmithKline. A Phase III randomized, open-label study comparing GSK1120212 to chemotherapy in subjects with advanced or metastatic BRAF V600E/K mutation-positive melanoma. November 2014. http://www.gsk-clinicalstudyregister.com/study/114267?csrf-token=1455140350.58%23% 23b84b9535ceb8c286571a3fbc99a10841244f5697&searchterms=trametinib&titles=&study-ids=&study-type=&document-type=&recruitment=&conditions=melanoma&compounds= &lead=&collaborators=&gender=&patientleveldata=&agefrom=&agefromtype=&ageto=&agetotype=&firstreceivefrom=&firstreceiveto=&lastupdatedfrom=&lastupdatedto=&country=&state=&search=Search#csr
20. Woods BS, Hawkins N, Scott DA. Network meta-analysis on the log-hazard scale, combining count and hazard ratio statistics accounting for multi-arm trials: a tutorial. BMC Med Res Methodol 2010;10:54.
21. Brunner HI, Ruperto N, Zuber Z, et al. Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. Ann Rheum Dis 2015;74:1110-17.
22. Ding Y, Fu H. Bayesian indirect and mixed treatment comparisons across longitudinal time points. Stat Med 2013;32:2613-28.
23. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195-206.
24. Scott DA, Woods B, Thompson JC, et al. Mortality and drug therapy in patients with chronic obstructive pulmonary disease: a network meta-analysis. BMC Pulm Med 2015;15:145.
25. Ambrosino N, Foglio K, Balzano G, et al. Tiotropium and exercise training in COPD patients: effects on dyspnea and exercise tolerance. Int J Chron Obstruct Pulmon Dis 2008;3:771-80.
26. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008;359:1543-54.
27. Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002;19: 217-24.
28. Brusasco V, Hodder R, Miravitlles M, et al. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003;58:399-404.
29. FDA. Highlights of prescribing information. KEYTRUDA. 2014. http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/125514lbl.pdf
30. Schroll JB, Abdel-Sattar M, Bero L. The Food and Drug Administration reports provided more data but were more difficult to use than the European Medicines Agency reports. J Clin Epidemiol 2015;68:102-7.
31. FDA. FDA Transparency Initiative. 2014. http://www.fda.gov/AboutFDA/Transparency/TransparencyInitiative/
32. EMA. European Medicines Agency policy on publication of clinical data for medicinal products for human use. 2014.
33. MacLean CH, Morton SC, Ofman JJ, et al. How useful are unpublished data from the Food and Drug Administration in meta-analysis? J Clin Epidemiol 2003;56:44-51.
34. Hart B, Lundh A, Bero L. Effect of reporting bias on meta-analyses of drug trials: reanalysis of meta-analyses. BMJ 2012;344:d7202.
35. McDonagh MS, Peterson K, Balshem H, et al. US Food and Drug Administration documents can provide unpublished evidence relevant to systematic reviews. J Clin Epidemiol 2013;66:1071-81.
36. Hopewell S, Collins GS, Boutron I, et al. Impact of peer review on reports of randomised trials published in open peer review journals: retrospective before and after study. BMJ 2014;349:g4145.
37. Rennie D. Suspended judgment. Editorial peer review: let us put it on trial. Control Clin Trials 1992;13:443-5.
38. Detsky AS, Naylor CD, O'Rourke K, et al. Incorporating variations in the quality of individual randomized trials into meta-analysis. J Clin Epidemiol 1992;45:255-65.
39. Rothstein HR, Sutton AJ, Borenstein M. Publication bias in meta-analysis. Prevention, assessment and adjustments. Wiley, 2005.
40. Norris SL, Holmer HK, Ogden LA, et al. Selective outcome reporting as a source of bias in reviews of comparative effectiveness. Rockville, MD: Agency for Healthcare Research and Quality, 2012.